Author name: carl@alteredquark.com

Oxford, UK and Cambridge, MA – (August 12, 2024) — SpyBiotech, a biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has appointed Dr. Prakash Bhuyan as Chief Medical Officer. Dr. Bhuyan is an infectious disease specialist with over 20 years of experience in academia and industry. […]

Oxford, UK and Cambridge, MA – (July 23, 2024) — SpyBiotech, a biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, announced today the completion of enrollment in its Phase I trial of SPYVLP01, a vaccine candidate targeting human cytomegalovirus (HCMV) using its Hepatitis B virus-like-particle platform technology.

Oxford, UK and Cambridge, MA – (June 18, 2024) — SpyBiotech, a biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has appointed Keith Dewedoff as Chief Financial Officer (CFO). Keith brings more than 20 years of experience in the life science industry to SpyBiotech, ranging from

— Agreement to support development of a vaccine against EBV — Oxford, UK and Cambridge, MA (May 23, 2024) — SpyBiotech, a biotechnology company with novel vaccine platform technologies that can target infectious diseases, cancer, and chronic diseases, today announced a sponsored research agreement with The University of Oxford for the development of a vaccine

— SpyBiotech’s lead program is targeting human cytomegalovirus (HCMV) — Oxford, UK and Cambridge, MA (December 7, 2023) — SpyBiotech, a biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, today announced that the first subject has been dosed with SPYVLP01, a candidate vaccine targeting human cytomegalovirus

— SpyBiotech’s lead program to target HCMV — Oxford, UK and Cambridge, MA (September 20, 2023) — SpyBiotech, a biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, announced that the company has filed a clinical trial application (CTA) with the U.K. Medicines and Healthcare products Regulatory

— Funding from the Bill & Melinda Gates Foundation will support development of next generation pan-SARS-CoV-2 and pan-sarbecovirus vaccines — Oxford, UK and Cambridge, MA (March 20, 2023) — SpyBiotech, a biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has received a grant of $4,094,561 from

Oxford, UK and Cambridge, MA (February 13, 2023) — SpyBiotech, a biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has appointed Eddie Gray, MBA, as Chairman of its Board of Directors. Gray joins the Board as an independent director. Gray has over forty years of global

— Novel Vaccine Company Expands Leadership Team and Establishes US Presence — Oxford, UK and Cambridge, MA (July 11, 2022) — SpyBiotech, a British biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has appointed Mark Leuchtenberger as its Chief Executive Officer (CEO). He also joins the

A research paper demonstrating the potential of SpyBiotech’s SpyCatcher/SpyTag vaccine platform has been published in Science Advances. A Covid-19 vaccine being developed with SpyBiotech’s technology elicited a strong immune response in non-human primates, showing titres of neutralising antibodies (>104) that were above the range of protection provided by other licensed vaccines in pre-clinical studies. The